Pharmacists are in a good position to counsel patients about Humulin R U-500 use, and should because some patients taking this highly concentrated form of insulin may not be using best practices, according to a paper presented at the 2019 Annual American Society of Health-System Pharmacists Midyear Clinical Meeting & Exposition.
Humulin R U-500 is FDA approved for use in patients who need more than 200 units of insulin per day. According to a poster presented by Alyssa Lee, PharmD, at the meeting, 12 of the 47 patients included in their retrospective evaluation were using a U-100 syringe when a U-500 syringe or Kwikpen would have been preferable. The researchers noted that these choices are if “insurance allows.”
Trending: The Most Common Pharmacy Penalties
The study researchers retrospectively examined observational medication data on 47 patients compiled between 2017 and the present from five different internal medicine settings to evaluate Humulin R U-500 use in patients with type 2 diabetes. The research team noted that the majority of U-500 users in their study population, about 60%, were being managed by a pharmacist, while 36% were managed by a primary care physician and 6% by an endocrinologist.
The researchers noted that use of Humulin R U-500 led to improvements in A1c without causing substantial weight gain; however, they noted a trend toward more severe hypoglycemia events in patients on twice a day compared with three times a day dosing.
Lee et al also noted that although the product is only FDA approved for use in patients utilizing more than 200 units of insulin a day, 20 of the patients were using less than 200 units daily.
The authors concluded that their data revealed a few prescribing practices that could use improvement and, they noted, a dosing guide for Humulin R U-500 is being developed to address the issues.
Lee A, Carson P, Morgan K, Sheehan L.. Medication Use Evaluation – Use of Humulin R U-500 insulin in the Primary Care Setting. Presented at ASHP Midyear Clinical Meeting & Exposition. December 8, 2019. Las Vegas, Nevada.